Please wait while the formulary information is being retrieved.
Drug overview for ISOVUE-M 200 (iopamidol):
Generic name: IOPAMIDOL
Drug class:
Therapeutic class: Diagnostic Agents
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
Generic name: IOPAMIDOL
Drug class:
Therapeutic class: Diagnostic Agents
No enhanced Introduction information available for this drug.
No enhanced Uses information available for this drug.
DRUG IMAGES
ISOVUE-M 200 41% VIAL
The following indications for ISOVUE-M 200 (iopamidol) have been approved by the FDA:
Indications:
Diagnostic imaging
Professional Synonyms:
Diagnostic imaging exam
Diagnostic imaging procedure
Diagnostic radiography
Diagnostic radiology
Indications:
Diagnostic imaging
Professional Synonyms:
Diagnostic imaging exam
Diagnostic imaging procedure
Diagnostic radiography
Diagnostic radiology
The following dosing information is available for ISOVUE-M 200 (iopamidol):
No enhanced Dosing information available for this drug.
No enhanced Administration information available for this drug.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for ISOVUE-M 200 (iopamidol):
There are 0 contraindications.
There are 2 severe interactions.
These drug interactions can produce serious consequences in most patients. Actions required for severe interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration scheduling, and providing additional patient monitoring. Review the full interaction monograph for more information.
| Drug Interaction | Drug Names |
|---|---|
| Metformin/Iodinated Contrast Materials SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: Use of iodinated contrast materials may result in acute changes in renal function, resulting in a decrease in metformin clearance.(1-3) CLINICAL EFFECTS: Use of iodinated contrast materials may increase levels of metformin, which may result in lactic acidosis.(1-3) PREDISPOSING FACTORS: Pre-existing renal dysfunction may contribute to decreased clearance of metformin. Other factors which may increase the risk for lactic acidosis include age greater than 65 years, dehydration, metabolic acidosis, sepsis, a history of hepatic impairment, alcoholism, or heart failure.(1-4) PATIENT MANAGEMENT: Evaluate renal function prior to contrast procedure. According to manufacturer recommendations, discontinue metformin at the time of, or prior to, the contrast imaging procedure in patients with a history of liver disease, alcoholism, heart failure, or if contrast is to be administered intra-arterially. When contrast is to be administered by other routes, discontinue metformin at the time of, or prior to, the procedure for patients with an estimated glomerular filtration rate (eGFR) of 30 to 60 mL/min/1.73 m2. Re-evaluate eGFR 48 hours after the imaging procedure and restart metformin if renal function is stable. Discontinuation of metformin is not required if eGFR is > 60 mL/min/1.73 m2.(4) According to American College of Radiology guidelines, discontinue metformin at the time of, or prior to, the contrast imaging procedure in patients with acute kidney injury or chronic kidney disease (Stage IV or V or eGFR < 30 mL/min/1.73 m2), or who are undergoing arterial catheter studies that might result in emboli (atheromatous or other) to the renal arteries. Re-evaluate eGFR 48 hours after the imaging procedure and restart metformin if renal function is normal. Discontinuation of metformin is not required in patients with no evidence of acute kidney injury and with eGFR >= 30 mL/min/m2.(5) DISCUSSION: An FDA review of the medical literature showed that metformin may be safely used in patients with mild or moderate renal impairment, resulting in modifications of prescribing recommendations and method for evaluation of renal function.(4) A clinical review of 33 patients on metformin who had received contrast media showed elevations in serum creatinine of the four patients with baseline elevations. The 29 patients with normal baseline renal function showed no elevations after administration of contrast media. The authors recommend that a baseline serum creatinine is obtained for all patients and that metformin should only be discontinued in patients with baseline elevations.(6) A retrospective study of ninety-seven patients currently taking metformin underwent a radiologic procedure with contrast media. Of these patients, 4 developed contrast material associated nephropathy and eight patients had an increased risk of lactic acidosis, with a baseline serum creatinine <1.5mg/dl.(7) A prospective clinical trial with 50 diabetic patients on metformin with baseline serum creatinine <1.47mg/dl showed no statistical difference in renal function before and 48 hours after administration of contrast media. The authors recommend a baseline serum creatinine for all patients and suggest that temporary discontinuation of metformin may not be necessary when baseline renal function is <1.47mg/dl.(8) A systematic review of the literature reveals that 17 of 18 case reports of metformin-induced lactic acidosis involved patients with renal dysfunction prior to administration of contrast media. The authors recommend a baseline serum creatinine in all patients and if renal dysfunction is present, metformin should be discontinued for 48 hours before and after administration of contrast media. The authors recommend follow-up creatinine measurement in patients with prior renal impairment or known comorbidities affecting lactate levels.(9) |
ACTOPLUS MET, ALOGLIPTIN-METFORMIN, DAPAGLIFLOZIN-METFORMIN ER, GLIPIZIDE-METFORMIN, GLYBURIDE-METFORMIN HCL, INVOKAMET, INVOKAMET XR, JANUMET, JANUMET XR, JENTADUETO, JENTADUETO XR, KAZANO, METFORMIN ER GASTRIC, METFORMIN ER OSMOTIC, METFORMIN HCL, METFORMIN HCL ER, PIOGLITAZONE-METFORMIN, RIOMET, SAXAGLIPTIN-METFORMIN ER, SEGLUROMET, SITAGLIPTIN-METFORMIN, SITAGLIPTIN-METFORMIN ER, SYNJARDY, SYNJARDY XR, TRIJARDY XR, XIGDUO XR, ZITUVIMET, ZITUVIMET XR |
| Methotrexate (Oncology-Injection)/Iodinated Contrast Media SEVERITY LEVEL: 2-Severe Interaction: Action is required to reduce the risk of severe adverse interaction. MECHANISM OF ACTION: One possible mechanism is renal dysfunction caused by the nephrotoxicity of both agents. CLINICAL EFFECTS: Concurrent use of iodinated contrast media may result in methotrexate toxicity, leading to increased risk of severe neurotoxicity, stomatitis, and myelosuppression, including neutropenia. PREDISPOSING FACTORS: Risk factors for methotrexate toxicity include: - High-dose oncology regimens - Impaired renal function, ascites, or pleural effusions PATIENT MANAGEMENT: It is recommended that the use of iodinated contrast media in patients receiving high dose methotrexate therapy be avoided until the serum methotrexate level is 0.1 mcmol/L or lower. With lower dose methotrexate therapy, iodinated contrast media should be used with caution and preventative measures should be considered.(1) DISCUSSION: There are three case reports of patients receiving concurrent iodinated contrast agents and methotrexate therapy developing methotrexate toxicity. One patient received iodinated contrast media the day after receiving a methotrexate infusion while the other two patients received contrast media 30 hours and 4.5 hours after methotrexate therapy.(1,2) |
METHOTREXATE, METHOTREXATE SODIUM |
There are 1 moderate interactions.
The clinician should assess the patient’s characteristics and take action as needed. Actions required for moderate interactions include, but are not limited to, discontinuing one or both agents, adjusting dosage, altering administration.
| Drug Interaction | Drug Names |
|---|---|
| Methotrexate (low strength injection, oral)/Iodinated Contrast Media SEVERITY LEVEL: 3-Moderate Interaction: Assess the risk to the patient and take action as needed. MECHANISM OF ACTION: One possible mechanism is renal dysfunction caused by the nephrotoxicity of both agents. CLINICAL EFFECTS: Concurrent use of iodinated contrast media may result in methotrexate toxicity, leading to increased risk of severe neurotoxicity, stomatitis, and myelosuppression, including neutropenia. PREDISPOSING FACTORS: Renal impairment PATIENT MANAGEMENT: It is recommended that the use of iodinated contrast media in patients receiving high dose methotrexate therapy be avoided until the serum methotrexate level is 0.1 mcmol/L or lower. With lower dose methotrexate therapy, iodinated contrast media should be used with caution and preventative measures should be considered.(1) DISCUSSION: There are three case reports of patients receiving concurrent iodinated contrast agents and methotrexate therapy developing methotrexate toxicity. One patient received iodinated contrast media the day after receiving a methotrexate infusion while the other two patients received contrast media 30 hours and 4.5 hours after methotrexate therapy.(1,2) |
JYLAMVO, METHOTREXATE, OTREXUP, RASUVO, TREXALL, XATMEP |
The following contraindication information is available for ISOVUE-M 200 (iopamidol):
Drug contraindication overview.
No enhanced Contraindications information available for this drug.
No enhanced Contraindications information available for this drug.
There are 0 contraindications.
There are 10 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Anuria |
| Dehydration |
| Hyperthyroidism |
| Intracerebral mass |
| Intracranial hypertension |
| Kidney disease with reduction in glomerular filtration rate (GFr) |
| Pheochromocytoma |
| Seizure disorder |
| Sickle cell disease |
| Thyrotoxicosis |
There are 4 moderate contraindications.
Clinically significant contraindication, where the condition can be managed or treated before the drug may be given safely.
| Moderate List |
|---|
| Asthma |
| Hypertension |
| Hypothyroidism |
| Kidney disease with likely reduction in glomerular filtration rate (GFr) |
The following adverse reaction information is available for ISOVUE-M 200 (iopamidol):
Adverse reaction overview.
No enhanced Common Adverse Effects information available for this drug.
No enhanced Common Adverse Effects information available for this drug.
There are 41 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Drug-induced hot flash |
Bradycardia Hypotension Urticaria |
| Rare/Very Rare |
|---|
|
Acute generalized exanthematous pustulosis Acute myocardial infarction Allergic dermatitis Anaphylaxis Angioedema Apnea Arterial thrombosis Asthma Bronchospastic pulmonary disease Cardiac arrhythmia Choking sensation Coma Dermal necrosis DRESS syndrome Dyspnea Hemorrhage Hypertension Hypothyroidism Laryngeal edema Myocardial ischemia Neutropenic disorder Paralysis Pulmonary edema Renal failure Seizure disorder Skin rash ST segment changes Stevens-johnson syndrome Syncope Throat constriction Thrombophlebitis Thyrotoxicosis crisis Toxic epidermal necrolysis Transient blindness Venous thrombosis Ventricular fibrillation Ventricular tachycardia |
There are 46 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Nausea |
Abnormal vasomotor function Flushing Kidney disease with reduction in glomerular filtration rate (GFr) Pain Sensation of warmth |
| Rare/Very Rare |
|---|
|
Abdominal pain with cramps Acute cognitive impairment Angina Anorexia Blurred vision Chest pain Chest tightness Chills Conjunctivitis Cough Dizziness Drowsy Dysgeusia Dysuria Erythema Eye tearing Facial edema Fever Headache disorder Hematuria Hyperhidrosis Injection site sequelae Malaise Memory impairment Muscle spasm Nasal congestion Pallor Paresthesia Periorbital edema Petechiae Pruritus of skin Rhinitis Sneezing Stinging of skin Tachycardia Tremor Urinary retention Vasodilation of blood vessels Visual changes Vomiting |
The following precautions are available for ISOVUE-M 200 (iopamidol):
No enhanced Pediatric Use information available for this drug.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
No enhanced Pregnancy information available for this drug.
No enhanced Lactation information available for this drug.
No enhanced Geriatric Use information available for this drug.
The following prioritized warning is available for ISOVUE-M 200 (iopamidol):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for ISOVUE-M 200 (iopamidol)'s list of indications:
No ICD codes found for this drug.
No ICD codes found for this drug.
Formulary Reference Tool